Institute of Dentistry, University of Turku, Turku, Finland.
Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
Cancer Rep (Hoboken). 2024 May;7(5):e2069. doi: 10.1002/cnr2.2069.
Only a few previous studies examine immune system recovery after completed cancer treatment.
The aim of this study was to analyze immune reconstitution after childhood cancer therapy in a non-hematopoietic stem cell transplantation setting.
We analyzed children (N = 79) who received chemotherapy with/without irradiation for cancer diagnosed between 2014 and 2019 at Turku University Hospital, Finland. We retrospectively collected data on baseline parameters and post-treatment immunological recovery, namely neutrophil and lymphocyte counts, IgG levels, CD19, CD4 and natural killer cell counts. Immunological parameters were followed until their normalization. Treatment intensity was stratified according to the Intensity of Treatment Rating Scale (ITR-3). We analyzed the effects of treatment intensity on normalization of immunological parameters across the entire treatment range. Treatment intensity had a major effect on immune system recovery after completion of treatment. Most patients had normal immunological parameters 1-4 months post-treatment both in high- and low-intensity treatment groups, but patients classified in the high-intensity group had low parameters more often than patients in the low-intensity group.
Our data suggest a fast recovery of studied immunological parameters after the majority of current pediatric oncologic treatments. Treatment for high-risk acute lymphoblastic leukemia, acute myeloid leukemia, medulloblastoma, and mature B-cell lymphoma was associated with prolonged recovery times for a substantial proportion of cases. High treatment intensity was associated with prolonged immunological recovery.
仅有少数既往研究探讨癌症治疗完成后的免疫系统恢复情况。
本研究旨在分析非造血干细胞移植背景下儿童癌症治疗后的免疫重建情况。
我们分析了芬兰于 2014 年至 2019 年期间在图尔库大学医院接受化疗联合/不联合放疗治疗的癌症患儿(N=79)。我们回顾性收集了基线参数和治疗后免疫恢复(即中性粒细胞和淋巴细胞计数、IgG 水平、CD19、CD4 和自然杀伤细胞计数)的数据。免疫参数一直随访至恢复正常。根据治疗强度评分(ITR-3)对治疗强度进行分层。我们分析了治疗强度对整个治疗范围内免疫参数正常化的影响。治疗强度对治疗完成后免疫系统的恢复有重大影响。大多数患者在高、低强度治疗组中,治疗后 1-4 个月免疫参数均恢复正常,但高强度组患者的参数较低的情况比低强度组患者更常见。
我们的数据表明,当前大多数儿科肿瘤治疗后,研究的免疫参数恢复迅速。对于高危急性淋巴细胞白血病、急性髓细胞白血病、髓母细胞瘤和成熟 B 细胞淋巴瘤的治疗,相当一部分患者的恢复时间延长。高强度治疗与免疫恢复时间延长相关。